申请人:Elan Pharmaceuticals, Inc.
公开号:US06410781B1
公开(公告)日:2002-06-25
Disclosed are compounds which bind &agr;4&bgr;7 integrin. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by &agr;4&bgr;7 integrin. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
揭示了结合α4β7整合素的化合物。其中某些化合物还抑制白细胞粘附,特别是由α4β7整合素介导的白细胞粘附。这些化合物在治疗哺乳动物患者(例如人类)的炎症性疾病方面非常有用,如哮喘、阿尔茨海默病、动脉粥样硬化、艾滋病痴呆、糖尿病、炎症性肠病、类风湿性关节炎、组织移植、肿瘤转移和心肌缺血。这些化合物还可以用于治疗多发性硬化等炎症性脑疾病。